InMed Pharmaceuticals IncNASDAQ:INMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3030
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2634/ 50
- Ask / Lots0.2850/ 4
- Open / Previous Close0.0000 / 0.3030
- Day Range---
- 52 Week Range
- Volume210
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INM |
|---|---|---|
| 09:32 ET | 1469 | 0.289 |
| 09:34 ET | 5799 | 0.28 |
| 09:50 ET | 500 | 0.276 |
| 09:54 ET | 4000 | 0.2711 |
| 09:56 ET | 247 | 0.272 |
| 09:57 ET | 192 | 0.279799 |
| 10:03 ET | 750 | 0.2797 |
| 10:08 ET | 1000 | 0.2797 |
| 10:12 ET | 100 | 0.2796 |
| 10:17 ET | 1400 | 0.2796 |
| 10:24 ET | 100 | 0.2796 |
| 10:32 ET | 5000 | 0.27485 |
| 10:35 ET | 1266 | 0.2797 |
| 10:44 ET | 543 | 0.274 |
| 10:46 ET | 3976 | 0.27001 |
| 10:51 ET | 200 | 0.2739 |
| 10:53 ET | 100 | 0.27195 |
| 11:00 ET | 10754 | 0.2739 |
| 11:04 ET | 14500 | 0.2797 |
| 11:06 ET | 2445 | 0.27979 |
| 11:13 ET | 100 | 0.2798 |
| 11:18 ET | 11507 | 0.2739 |
| 11:20 ET | 904 | 0.279 |
| 11:33 ET | 347 | 0.2764 |
| 11:36 ET | 1300 | 0.2797 |
| 11:40 ET | 1500 | 0.27872 |
| 11:42 ET | 8687 | 0.2899 |
| 11:47 ET | 6467 | 0.2899 |
| 11:49 ET | 3600 | 0.2878 |
| 11:54 ET | 5507 | 0.29 |
| 11:56 ET | 4199 | 0.29 |
| 11:58 ET | 6910 | 0.289776 |
| 12:02 ET | 445 | 0.29 |
| 12:05 ET | 1650 | 0.2898 |
| 12:07 ET | 3300 | 0.286699 |
| 12:18 ET | 2200 | 0.286699 |
| 12:20 ET | 200 | 0.2894 |
| 12:39 ET | 100 | 0.2893 |
| 12:41 ET | 1700 | 0.2893 |
| 12:50 ET | 30339 | 0.2894 |
| 12:52 ET | 9864 | 0.296 |
| 12:56 ET | 184498 | 0.2746 |
| 12:57 ET | 24000 | 0.2875 |
| 12:59 ET | 9100 | 0.295999 |
| 01:01 ET | 10100 | 0.294 |
| 01:06 ET | 1488 | 0.2939 |
| 01:08 ET | 7880 | 0.295 |
| 01:10 ET | 29408 | 0.2854 |
| 01:12 ET | 11450 | 0.2952 |
| 01:14 ET | 5200 | 0.29 |
| 01:15 ET | 21355 | 0.2893 |
| 01:17 ET | 2427 | 0.2926 |
| 01:19 ET | 818 | 0.296 |
| 01:21 ET | 41561 | 0.307 |
| 01:24 ET | 52770 | 0.3068 |
| 01:26 ET | 20482 | 0.3069 |
| 01:28 ET | 41015 | 0.3099 |
| 01:30 ET | 31099 | 0.3076 |
| 01:32 ET | 69498 | 0.3049 |
| 01:33 ET | 18576 | 0.3018 |
| 01:35 ET | 3000 | 0.31 |
| 01:37 ET | 12489 | 0.3048 |
| 01:39 ET | 100 | 0.3048 |
| 01:42 ET | 2900 | 0.3049 |
| 01:44 ET | 71333 | 0.3042 |
| 01:46 ET | 2100 | 0.2999 |
| 01:51 ET | 1465 | 0.298 |
| 02:04 ET | 15200 | 0.2989 |
| 02:06 ET | 1200 | 0.2896 |
| 02:08 ET | 21546 | 0.2999 |
| 02:09 ET | 12100 | 0.294949 |
| 02:11 ET | 10399 | 0.2947 |
| 02:13 ET | 3221 | 0.299899 |
| 02:15 ET | 100 | 0.2989 |
| 02:22 ET | 15800 | 0.294899 |
| 02:24 ET | 222 | 0.2948 |
| 02:26 ET | 5250 | 0.292 |
| 02:27 ET | 8700 | 0.2999 |
| 02:29 ET | 26000 | 0.2999 |
| 02:31 ET | 17547 | 0.3 |
| 02:33 ET | 38982 | 0.31 |
| 02:36 ET | 825 | 0.3099 |
| 02:40 ET | 1300 | 0.3012 |
| 02:42 ET | 100 | 0.3002 |
| 02:44 ET | 300 | 0.3099 |
| 02:51 ET | 9000 | 0.3056 |
| 02:54 ET | 21122 | 0.3036 |
| 02:56 ET | 3100 | 0.2976 |
| 02:58 ET | 29801 | 0.305599 |
| 03:00 ET | 1473 | 0.3056 |
| 03:02 ET | 2300 | 0.2952 |
| 03:03 ET | 12700 | 0.2988 |
| 03:07 ET | 10600 | 0.2925 |
| 03:09 ET | 26000 | 0.2908 |
| 03:12 ET | 28099 | 0.2921 |
| 03:14 ET | 7055 | 0.291042 |
| 03:16 ET | 8982 | 0.2902 |
| 03:18 ET | 12600 | 0.2943 |
| 03:20 ET | 22894 | 0.2898 |
| 03:23 ET | 250 | 0.2898 |
| 03:27 ET | 145 | 0.2858 |
| 03:32 ET | 300 | 0.2898 |
| 03:36 ET | 1000 | 0.2865 |
| 03:41 ET | 1000 | 0.285701 |
| 03:43 ET | 100 | 0.282 |
| 03:45 ET | 27156 | 0.2821 |
| 03:48 ET | 21598 | 0.2864 |
| 03:50 ET | 2528 | 0.28785 |
| 03:52 ET | 21276 | 0.3 |
| 03:54 ET | 10333 | 0.2998 |
| 03:56 ET | 5107 | 0.2998 |
| 03:57 ET | 729065 | 0.310534 |
| 03:59 ET | 616400 | 0.303 |
Apr 18, 2024
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board, from 8:02AM ET on Thursday Apr 18, 2024 by Dow Jones
8:02AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 16, 2024
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration, from 8:02AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:02AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 4, 2024
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies, from 8:01AM ET on Thursday Apr 04, 2024 by Dow Jones
8:01AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
InMed Pharmaceuticals Inc | 1.8M | -0.2x | --- |
Histogen Inc | 1.5M | -0.1x | --- |
Stemtech Corp | 6.0M | -0.9x | --- |
Aridis Pharmaceuticals Inc | 2.8M | -0.3x | --- |
Antigenics Inc | 2.4K | 0.0x | --- |
Athersys Inc | 277.7K | 0.0x | --- |
Company Information
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.
Contact Information
- Headquarters
- SUITE 310, 815 W. HASTINGS STREETVANCOUVER, BC, Canada V6C 1B4
- Phone
- 604-669-7207
- Fax
- 778-945-6800
Executives
- Independent Chairman of the Board
- Andrew Hull
- President, Chief Executive Officer, Director
- Eric Adams
- Chief Financial Officer, Corporate Secretary
- N. Netta Jagpal
- Chief Operating Officer
- Michael Woudenberg
- Senior Vice President - Preclinical Research and Development
- Eric Hsu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8M |
|---|---|
Revenue (TTM) | $5.5M |
Shares Outstanding | 6.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-1.65 |
Book Value | $3.63 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -127.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
